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In May 2015, Professor Xiao Yang authored a review on the development of CRISPR-Cas9 techniques in the journal of
Military Medical Research. This review provided a valuable overview of this major scientific advance. It has been four years
since the first publication of the CRISPR-Cas9 breakthrough (Science. 2012; 337: 816–21). The use of this technique has
expanded into various scientific areas and is being developed into a systematic technical platform that may contribute
to many bioengineering fields involving DNA sequence editing.
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Dear editor,
In May 2015, Professor Xiao Yang authored a review
on the development of CRISPR-Cas9 technique in the
journal of Military Medical Research [1]. This review
provided a valuable overview of this major scientific
advance. It has been four years since the first publication
of the CRISPR-Cas9 breakthrough [2]. The use of this
technique has expanded into various scientific areas and
is being developed into a systematic technical platform
that may contribute to many bioengineering fields
involving DNA sequence editing.
The advantages of the CRISPR(Clustered Regularly
Interspaced Short Palindromic Repeats)-Cas9 technology
include its economy, high efficiency, precise targeting
and flexible technical extension compared with traditional
DNA sequence modifying measures such as transcription
activator-like effector nuclease (TALEN,transcription
activator-like (TAL) effector nucleases) [3]. The published
literature has shown the utility of CRISPR-Cas9 in both
DNA sequence knock-in and knock-out contexts. The
alterations can range from single nucleotide editing to the
modification of multiple genome-wide genomic sites
[4, 5]. It is easy to delete genes in cells or to create genetic-
ally modified karyotypes [6]. The CRISPR-Cas-9 strategy* Correspondence: qianhaili001@163.com
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life processes and disease development. The technology
may also be used as a potential “surgical knife” to correct
genomic mutations or create new creatures by changing
the inherited phenotypes. In addition to the genomic
engineering applications that professor Xiao Yang men-
tioned, the protospacer adjacent motif (PAM) sequence-
limited specificity of the CRISPR-Cas9 system has been
used to circumvent engineering Cas9 derivatives. This
property provides flexibility to CRISPR-Cas9 targeting
strategies [7]. Poulami et al. also found another aspect of
CRISPR-mediated immunity. The authors found the Type
III CRISPR-Cas immune system was able to cleave DNA
and RNA during infection [8]. The technique of CRISPR-
Cas9 is still in development. If nonhomologous end joining
activity is inhibited in vivo, then the efficiency of precise
genome editing with CRISPR-Cas9 can be substantially
increased [9].
The CRISPR-Cas9 technology does have limitations
associated with targeting ability. Several off-target muta-
tions have been detected by genome-sequencing due to
its high specificity. This prohibits its potential use in
correcting disease-associated mutations [10]. The rapidly
expanding application of the CRISPR-Cas9 technique
also creates an ethical controversy because it may be
used to manipulate human germ cells. Manipulating
human germ cells using CRISPR-Cas9 does not present
technical obstacles. However, its potential off-targetis distributed under the terms of the Creative Commons Attribution 4.0
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individual is created with this tool. Each additional step
forward will further improve the technology. Therefore,
this technique should be used cautiously before modifying
human inheritance. A recent publication in the journal
Protein & Cell by Junjiu Huang’s group in China revealed
the first attempt to modify human tripronuclear zygotes
[11]. This report caused a fierce debate regarding whether
this research is breaking the ethical ban on modifying the
human germ cell genome [12, 13]. Simultaneously, a pro-
ject led by George Church at Harvard University tried to
correct genomic BRCA1(BREAST CANCER 1) mutations
to decrease the risk of breast cancer in the next gener-
ation. This study was suspended indefinitely. In addition
to the ethical concerns, there are technical concerns to
address. The current CRISPR-Cas9 technique is not suffi-
ciently mature to adjust human inheritance. The first issue
is that CRISPR-Cas9 induces off-target changes to the
genome. The second possible issue is that not all of the
functions of the candidate gene are fully understood.
Therefore, we cannot appreciate the consequences of gen-
ome editing in offspring.
While we are joyfully celebrating the progress brought
to science by the development of CRISPR-Cas9, we must
use caution in applying this technology.
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